Journal
INFLAMMATORY BOWEL DISEASES
Volume 16, Issue 6, Pages 925-932Publisher
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.21284
Keywords
inflammatory bowel disease; Crohn's disease; ulcerative colitis; hepatitis A; hepatitis B; hepatitis C; viral hepatitis; vaccination
Categories
Ask authors/readers for more resources
Viral hepatitis is common worldwide and in the United States. Inflammatory bowel disease (IBD) patients with chronic hepatitis B virus (HBV) with active disease (elevated alanine aminotransferase level and viral replication) should receive HBV treatment. HBV reactivation is associated with significant morbidity and mortality in patients receiving immunosuppression. IBD patients may require long-term immunosuppression, and therefore should be considered candidates for vaccination against new HBV infection as well as prophylaxis against HBV reactivation prior to immunosuppressive therapy. Tumor necrosis factor alpha antagonists and immunomodulators appear compatible with use in IBD patients with HCV, although prednisone may increase viral replication. HCV treatment with peg-interferon and ribavirin may exacerbate gastrointestinal symptoms, and therefore the decision to treat HCV needs to be individualized. Management of IBD patients with viral hepatitis is addressed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available